Alkermes

ALKS | NASDAQ

Price Alert Chart Builder DCF Calculator

$43.29

-$0.89 (-2.01%)

Sep 22, 2026, 4:00 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Pro Subscription

Upgrade now for unlimited access to all data, tools and no ads.

Upgrade now ➞

Related Stocks

Company	Yield
ACAD ACADIA Pharmaceuticals	N/A
ARWR Arrowhead Pharmaceuticals	N/A
CRSP CRISPR Therapeutics	N/A
KYMR Kymera Therapeutics	N/A
PCVX Vaxcyte	N/A
PTCT PTC Therapeutics	N/A
PTGX Protagonist Therapeutics	N/A
TGTX TG Therapeutics	N/A

Dividend Rankings ➞

Recent News

1 day ago / zacks.com
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
2 days ago / investors.com
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won
2 days ago / businesswire.com
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
7 days ago / businesswire.com
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
8 days ago / defenseworld.net
California State Teachers Retirement System Increases Holdings in Alkermes plc $ALKS
12 days ago / seekingalpha.com
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise
13 days ago / businesswire.com
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
27 days ago / zacks.com
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?
30 days ago / businesswire.com
The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
1 month ago / zacks.com
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know